Price TargetProjected revenues for the next 12 months are lowered, resulting in a reduced price target of $27 per share.
Revenue DeclineThe company exceeded revenue projections for 3Q24 with total revenue of $30.6M, despite an 8% YoY decline due to divestitures.
Revenue GuidanceBioLife lowered revenue guidance to $98M-$100M, from $99M-$101M, to factor in the reduction of the SciSafe divestiture.